financetom
Business
financetom
/
Business
/
Cherry Bekaert Set to Acquire Pennsylvania-Based Herbein + Company, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cherry Bekaert Set to Acquire Pennsylvania-Based Herbein + Company, Inc.
Oct 8, 2025 5:26 AM

RALEIGH, N.C., Oct. 8, 2025 /PRNewswire/ -- Cherry Bekaert (the Firm) is pleased to announce its intent to acquire the business of Herbein + Company, Inc. (Herbein), a CPA advisory firm providing tax, audit, advisor, HR consulting and risk management services in a transaction expected to close later this month. As a Top 100 firm on INSIDE Public Accounting's (IPA) list, Herbein brings extensive experience in agribusiness, construction, financial institutions, manufacturing, higher education and government industries to Cherry Bekaert.

Cherry Bekaert will acquire Herbein + Company, Inc., a Top 100 CPA firm.

Herbein, headquartered in Reading, Pennsylvania, with additional offices throughout the commonwealth, represents Cherry Bekaert's inaugural expansion into Pennsylvania. Herbein also operates offices in Delaware and New Jersey. This acquisition strengthens Cherry Bekaert's connectivity across the northeastern, mid-Atlantic and midwestern regions. Herbein's client base — which includes family-owned business, private equity, business enterprise and privately held business clients — aligns with Cherry Bekaert's existing clientele.

Michelle Thompson, Chief Executive Officer of Cherry Bekaert Advisory LLC, stated: "This acquisition not only expands our geographical reach into Pennsylvania but also enhances our service offerings across key industries. Herbein's client-centric approach aligns well with our Firm's values and strategic objectives. Together, we look forward to driving greater value for our clients and further strengthening our regional presence."

David Stonesifer, Partner and Chief Executive Officer of Herbein + Company, Inc., commented: "We are excited for this new chapter with Cherry Bekaert. Our clients will benefit from an expanded suite of offerings while still receiving the same level of service they have come to expect from Herbein."

As is typical for firms that operate in alternative practice structures, the transaction would consist of two acquisitions: Cherry Bekaert Advisory LLC would acquire Herbein + Company, Inc.'s nonattest assets while Cherry Bekaert LLP would acquire Herbein + Company, Inc.'s attest assets. The integration will be seamless, with both firms maintaining the high standards of service expected by their clients. The unified team will operate under the Cherry Bekaert brand.

About Cherry Bekaert

Cherry Bekaert, ranked among the largest assurance, tax, and advisory firms in the U.S., serves clients across industries in the U.S. and internationally. "Cherry Bekaert" is the brand name under which Cherry Bekaert LLP and Cherry Bekaert Advisory LLC, independently owned entities, provide professional services in an alternative practice structure in accordance with applicable professional standards. Cherry Bekaert Advisory LLC is not a licensed CPA firm. Cherry Bekaert LLP is a licensed CPA firm that provides attest services, and Cherry Bekaert Advisory LLC and its subsidiary entities provide business advisory and non-attest services spanning the areas of transaction advisory, risk and accounting advisory, digital solutions, cybersecurity, and tax. We exercise a deliberate curiosity to know our clients' industries and work collaboratively to create shared success. For more details, visit cbh.com/disclosure.

Cherry Bekaert LLP and Cherry Bekaert Advisory LLC are members of Allinial Global, an accountancy and business advisory global association. Visit us at cbh.com and follow us on LinkedIn, Facebook,X or Instagram.

© 2025 Cherry Bekaert. All Rights Reserved.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cherry-bekaert-set-to-acquire-pennsylvania-based-herbein--company-inc-302577163.html

SOURCE Cherry Bekaert

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exclusive-International Paper to win EU approval for $7.1 billion DS Smith deal
Exclusive-International Paper to win EU approval for $7.1 billion DS Smith deal
Jan 21, 2025
BRUSSELS (Reuters) -U.S.-based International Paper ( IP ) is set to get EU approval for its 5.8 billion pound ($7.12 billion) purchase of UK rival DS Smith ( DITHF ) after agreeing to sell assets to address competition concerns, people with direct knowledge of the matter said on Tuesday. The deal announced last April will boost International Paper's ( IP...
Tempus AI Stock Is Trading Higher Tuesday: What's Going On?
Tempus AI Stock Is Trading Higher Tuesday: What's Going On?
Jan 21, 2025
Tempus AI Inc ( TEM ) shares are trading higher Tuesday after former House Speaker Nancy Pelosi disclosed a new position in the technology company. What Happened: Pelosi disclosed in a new filing that she purchased 50 call options in Tempus AI ( TEM ) on Jan. 14 with a strike price of $20. The value of the calls is between $50,000...
US energy mergers may slow in 2025 as deal sizes shrink, says Enverus
US energy mergers may slow in 2025 as deal sizes shrink, says Enverus
Jan 21, 2025
(Reuters) - The pace of U.S. upstream public-to-public mergers could slow in 2025 from their recent average of five per year along with a fall in deal sizes, according to a report from energy analytics firm Enverus that was released on Tuesday. The consolidation trend in the U.S. energy sector, which triggered deals amounting to $250 billion in 2023, stretched...
Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal
Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal
Jan 21, 2025
09:15 AM EST, 01/21/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Tuesday that it will receive a $200 million upfront payment from Takeda Pharmaceutical ( TAK ) in connection to a global development and commercialization license deal to advance elritercept. The license agreement with Takeda took effect on Jan. 16, the biopharmaceutical company said. Keros shares were up...
Copyright 2023-2026 - www.financetom.com All Rights Reserved